Acute promyelocytic leukemia (APL) is characterized by the appearance of blasts,
insensitive to physiological retinoic acid (RA)-dependent differentiation and in the majority of …

The histone demethylase LSD1 is deregulated in several tumors, including leukemias,
providing the rationale for the clinical use of LSD1 inhibitors. Treatment of AML cells with …

The histone demethylase LSD1 is deregulated in several tumors, including leukemias,
providing the rationale for the clinical use of LSD1 inhibitors. In acute promyelocytic …

Abstract Acute Myeloid Leukemia (AML) represents a diverse category of blood cancers
marked by the clonal proliferation of atypical myeloid precursor cells within the bone …

Abstract Lysine Specific Demethylase 1 (LSD1 or KDM1A) is one of a number of epigenetic
regulators which have recently emerged as candidate therapeutic targets in acute myeloid …

Recent investigations indicate that epigenetic regulators act at the initial step of myeloid
leukemogenesis by forming pre-leukemic hematopoietic stem cells (HSCs), which possess …

Lysine-Specific Demethylase 1 (LSD1) is a protein lysine demethylase that catalyzes the
removal of methyl-groups from the mono-and di-methylated forms of lysine 4 and lysine 9 of …

Lysine-specific histone demethylase 1 (LSD1/KDM1A) governs hematopoiesis by regulating
hematopoietic stem cell renewal and proper differentiation. Additionally, LSD1 is required for …

Abstract Lysine specific demethylase 1 (LSD1) is a histone H3K4me1/2 demethylase found
in various transcriptional co-repressor complexes. These complexes include Histone …

The histone demethylating enzyme LSD1 has emerged as a promising epigenetic target in
the treatment of acute myeloid leukemia (AML). Inhibition of LSD1 has been shown to …